Moody’s downgrades Senegal to Caa1 amid rising debt concerns
REDWOOD CITY, Calif. - Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company with a market capitalization of $8.43 billion and impressive revenue growth of 25.7% over the last twelve months, will present new data from its Phase 3 ROSELLA trial at the European Society for Medical Oncology (ESMO) Annual Meeting on Sunday, October 19, 2025, the company announced in a press release. According to InvestingPro analysis, the company maintains excellent financial health with a strong current ratio of 3.06.
The presentation will focus on results from patients with platinum-resistant ovarian cancer who were previously treated with PARP inhibitors, a group with particularly poor prognosis. The data will be featured in a late-breaking oral presentation during the Gynaecological cancers session. The company’s strong financial position, with minimal debt and robust cash flows, positions it well to advance this critical research program.
The ROSELLA trial is evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The study is being conducted in collaboration with several international oncology research groups, including The GOG Foundation, the European Network of Gynaecological Oncological Trial groups, and others.
Relacorilant is an oral selective glucocorticoid receptor antagonist that modulates cortisol activity. The drug has received orphan drug designation from both the FDA and European Commission for hypercortisolism treatment, and from the EC for ovarian cancer treatment.
The FDA has assigned a Prescription Drug User Fee Act date of December 30, 2025, for relacorilant as a treatment for hypercortisolism, and July 11, 2026, for its use in platinum-resistant ovarian cancer.
Platinum-resistant ovarian cancer affects approximately 20,000 women annually in the United States, with a similar number in Europe. The median overall survival following recurrence is about 12 months with current single-agent chemotherapy options. With analyst price targets ranging from $121 to $145, market experts appear optimistic about Corcept’s potential in this space. For deeper insights into Corcept’s valuation and growth prospects, including 16 additional ProTips, visit InvestingPro, where you’ll find comprehensive analysis and the detailed Pro Research Report available exclusively to subscribers.
In other recent news, Corcept Therapeutics reported its Q2 2025 earnings, surpassing expectations with an earnings per share (EPS) of $0.29, which was 52.63% higher than the forecasted $0.19. However, the company’s revenue slightly missed projections, coming in at $194.4 million compared to the anticipated $199.4 million. In regulatory developments, the U.S. Food and Drug Administration accepted Corcept’s New Drug Application for relacorilant as a treatment for platinum-resistant ovarian cancer. This application is supported by data from the company’s Phase 3 ROSELLA and Phase 2 clinical trials, which demonstrated improved progression-free and overall survival rates. The FDA has set a Prescription Drug User Fee Act date for July 11, 2026. These developments highlight significant milestones for Corcept Therapeutics in both its financial performance and its efforts in advancing cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.